Lilly acquires Locemia’s intranasal glucagon powder

Eli Lilly has acquired worldwide rights to Locemia Solution’s intranasal glucagon, which is in Phase 3 development for the treatment of severe hypoglycemia in diabetics who use insulin, the two companies said. The dry powder glucagon formulation is delivered by a single-use intranasal puffer. No financial terms were disclosed. Lilly Diabetes President Enrique Conterno commented, . . . Read more

OptiNose raises up to $30 million for development of intranasal fluticasone

OptiNose has announced the closing of a financing round of up to $30M, which it plans to use for continued development and commercialization of its OPN-375 intranasal fluticasone as well as for additional pipeline products. The company had announced completion of its previous round of financing in August 2014. According to the company, Phase 3 . . . Read more

InCarda gets patents for inhaled cardiovascular therapies

InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company’s inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No. 8,974,828, issued in March 2015 and titled, “Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration.” . . . Read more